Clinuvel Pharmaceuticals Ltd (CLVLF) stock

CLVLFOTCAmerican Depositary ReceiptsFiscal year ends June 30Also trades as CUVL

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Oct 30, 2026Score 9/30

$5.05−0.33 (-6.13%)

Close on Oct 19, 2026Market cap $254.66MP/E 11.0Yield –

Clinuvel Pharmaceuticals operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

For fiscal 2026 it was $27.92M, up 5.3% from the year before.

Period	Period end	Value	Change
FY2026	Jun 30, 2026	$27.92M	+5.3%
FY2025	Jun 30, 2025	$26.52M	-7.0%
FY2024	Jun 30, 2024	$28.53M	–

Parsed from the XBRL in Clinuvel Pharmaceuticals's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is CLVLF.

Revenue growth5.2% · median 17.8%

Gross margin82.9% · median 69.2%

Operating margin43.4% · median -14.2%

Net margin36.0% · median 23.5%

Advertisement
300 × 250

See a number that looks wrong?